Biotech Stocks Healthcare Stocks Life Sciences

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff could look at. For those who don't know what the patent…

ByNick Sundich

04

Dec 2024

Uncategorized

Here are 6 of the worst performing ASX shares. Will they bounce back in 2025?

6 of the worst performing ASX shares. Will they bounce back in 2025? Imugene (ASX:IMU) down 65% in 2024 Imugene is an oncology biotech. It is still capped at over…

ByNick Sundich

22

Oct 2024

Healthcare Stocks Life Sciences

Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months

Imugene (ASX:IMU) is still valued at over $400m, in spite of being valued at over $2bn back in 2021 and having had a rollercoaster 12 months. Imugene (ASX:IMU) share price chart,…

ByNick Sundich

29

May 2024

News

Will the RBA Cut Interest Rates in 2024 and, if So, Which Stocks Should I Buy?

The Reserve Bank of Australia (RBA) has been a focal point of economic discussions in 2024. With the cash rate at a 12-year high of 4.35%, Australians are eagerly anticipating…

ByUjjwal Maheshwari

24

May 2023

Education

Is $100 or more an expensive share price? Here’s why it’s not

With few ASX companies with share prices over $100, you'd be forgiven for thinking it is an expensive share price. Overseas, share prices higher than $100 is far more common. Granted,…

ByNick Sundich

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

Here are 6 of the worst performing ASX shares. Will they bounce back in 2025?

Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months

Will the RBA Cut Interest Rates in 2024 and, if So, Which Stocks Should I Buy?

Is $100 or more an expensive share price? Here’s why it’s not

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here